| Tao Ren,Yan Wu. Efficacy and adverse reactions of apatinib as secondline or later-line treatment in advanced lung cancer. Oncol Transl Med, 2021, 7: 160-164. |
| 甲磺酸阿帕替尼治疗二线及以上III/IV期肺癌的疗效及不良反应分析 |
| Efficacy and adverse reactions of apatinib as secondline or later-line treatment in advanced lung cancer |
| Received:November 10, 2020 Revised:July 09, 2021 |
| DOI：10.1007/s10330-020-0468-8 |
| 中文关键词: log-rank检验；甲磺酸阿帕替尼；晚期肺癌；预后 |
| 英文关键词: Log-rank regression analysis; apatinib; advanced lung cancer; prognostic factors |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Tao Ren | The First People’s Hospital of Nanning, Nanning 530022, China | rentao197904@163.com | | Yan Wu* | The First Affiliated Hospital of Xi’an Medical University, Xi’an 710077, China | wuyan57968@163.com |
|
| Hits: 5718 |
| Download times: 6522 |
| 中文摘要: |
| 目 的 评价甲磺酸阿帕替尼治疗二线及以上III/IV期肺癌有效性和安全性，以及影响预后的因素。方 法 收集2018年1月-2018年12月于我院确诊并已经进行二线及以上治疗的III/IV期肺癌60例，患者均采用阿帕替尼单药口服，425mg/d,28d/疗程,治疗一个疗程。回归分析所有患者的缓解率，疾病控制率，不良反应及对预后情况产生影响的相关因素。结 果 60例患者经过治疗后，总缓解率为6.7%，疾病控制率为61.7%（37/60）。无进展生存期（3.2±0.1）个月，总生存期（5.3±0.5）个月；3-4级不良反应总发生率为15.0%（9/60），通过降低药物剂量或者暂停用药后不良反应均得到显著缓解；分化程度、ECOG评分及不良反应均为影响阿帕替尼治疗预后的显著因素（P＜0.05）；组织分化程度、ECOG评分及不良反应均为影响患者接受阿帕替尼治疗预后的独立危险因素（P＜0.05）。结 论 分析结果表明阿帕替尼能够有效的抑制III/IV期肺癌患者的病情进展，延长患者生存期，且毒副作用相对较小，利于患者耐受；分化程度、ECOG评分及不良反应均能够对接受阿帕替尼患者预后产生影响。 |
| 英文摘要: |
| Objective The objective was to investigate the prognostic factors of advanced lung cancer treated with
apatinib by log-rank regression analysis.
Methods Sixty patients with advanced stage lung cancer confirmed at The First People’s Hospital of
Nanning between January 2018 and December 2018 who had received a second-line treatment or a
treatment above this level were included. All patients were treated with 425 mg/d apatinib orally for a 28-
day course of treatment. Log-rank regression analysis of remission rates, disease control rates, adverse
events, and prognostic factors in all patients was performed.
Results After treatment, the total remission rate was 6.7%, and the disease control rate was 61.7%
(37/60). Progression-free survival was 3.2 ± 0.1 months, and overall survival was 5.3 ± 0.5 months. The
overall incidence of grade 3–4 adverse reactions was 15.0% (9/60), and these adverse reactions were
significantly relieved by reducing the drug dose or suspending drug use. Differentiation degree, Eastern
Cooperative Oncology Group (ECOG) score, and adverse reactions were all important and independent
risk factors affecting the prognosis of patients (P < 0.05).
Conclusion Apatinib treatment could effectively inhibit the progress of the disease for patients with
advanced lung cancer and prolong their survival with relatively mild toxicity and side effects, which is
beneficial to patient tolerance. Moreover, the degree of differentiation, ECOG score, and adverse reactions
could affect the prognosis of patients. |
|
View Full Text
Download reader HTML全文 |
| Close |